证券代码：600976 证券简称：健民集团 公告编号：2026-004 健民药业集团股份有限公司 第十一届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司于 2026 年 3 月 9 日发出召开第十一届董事会第七 次会议的通知，并于 2026 年 3 月 19 日在湖北省武汉市汉阳区鹦鹉大道 484 号公司 会议室召开。会议应出席董事 9 人，实际出席董事 9 人，符合《公司法》和《公司 章程》的规定。本次会议由袁平东董事长主持，经到会董事充分讨论，审议通过如 下议案： 1.公司 2025 年总裁工作报告 同意：9 票 弃权：0 票 反对：0 票 2.公司 2025 年董事会工作报告 同意：9 票 弃权：0 票 反对：0 票 本议案需提交股东会审议。 详见上海证券交易所网站（http://www.sse.com.cn）公司披露的《健民药业 集团股份有限公司 2025 年董事会工作报告》 3.公司 2025 年独立董事述职报告 同意：9 票 弃权：0 票 反对：0 票 本议 ...

健民药业集团股份有限公司 关于 2025 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600976 证券简称：健民集团 公告编号：2026-005 1、公司拟向全体股东每 10 股派发现金红利 9.00 元（含税）。截至 2025 年 12 月 31 日，公司总股本 153,398,600 股，并以此计算 2025 年年度合计拟派发 现金红利为人民币 138,058,740.00 元（含税），本年度现金分红占报告期内合并 报表中归属于上市公司股东的净利润比例为 38.37%。最终实际分配总额以实施 权益分派股权登记日时有权参与本次权益分派的总股数为准计算。 2、公司本年度不向全体股东送红股、也不进行资本公积金转增股本。 3、本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发 生变动的，拟维持分配总额不变，相应调整每股分配比例，并将在相关公告中披 露。 项目 本年度 上年度 上上年度 现金分红总额（元） ...

Financial Performance - The company's operating revenue for 2025 was CNY 3,369,908,369.13, a decrease of 3.85% compared to CNY 3,504,986,068.51 in 2024[20]. - The total profit for 2025 was CNY 391,057,169.72, reflecting a slight decrease of 0.40% from CNY 392,621,466.78 in the previous year[20]. - The net profit attributable to shareholders for 2025 was CNY 359,841,141.67, down 0.65% from CNY 362,178,656.98 in 2024[20]. - The basic earnings per share for 2025 were CNY 2.37, a decrease of 0.42% from CNY 2.38 in 2024[21]. - The weighted average return on net assets for 2025 was 14.26%, down 1.42 percentage points from 15.68% in 2024[21]. Revenue Breakdown - The pharmaceutical commercial sector's revenue decreased by 23.37%, while the pharmaceutical industrial sector's revenue grew by 15.92%[21]. - In Q1 2025, the company's operating revenue was approximately CNY 892.08 million, with a net profit attributable to shareholders of CNY 110.18 million[24]. - In Q2 2025, the operating revenue increased to approximately CNY 912.51 million, maintaining a net profit of CNY 110.45 million[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses in Q3 2025 was CNY 60.22 million, a decrease compared to previous quarters[24]. - The company achieved a revenue of 3.505 billion yuan in the Chinese herbal medicine industry, ranking 24th among listed companies in the sector for the 2024 fiscal year[38]. Cash Flow and Assets - The net cash flow from operating activities increased by 17.19% to CNY 274,529,817.46, primarily due to increased sales collections in the pharmaceutical industrial sector[20][21]. - The company's total assets at the end of 2025 were CNY 4,526,894,996.61, a 5.83% increase from CNY 4,277,629,406.13 in 2024[20]. - The net assets attributable to shareholders increased by 9.08% to CNY 2,656,393,006.53 compared to CNY 2,435,305,586.88 in 2024[20]. Research and Development - The company has made significant investments in R&D, focusing on innovative traditional Chinese medicine, with five new drug clinical trials currently underway[38]. - The company filed for 7 new patents and received 5 authorized patents during the reporting period, indicating a strong focus on R&D[75]. - The total R&D investment amounted to 115,656,436.32, representing 3.43% of total revenue[95]. - The company is focusing on innovative R&D in traditional Chinese medicine, particularly in pediatrics, gynecology, and chronic diseases[121]. Product Development and Launches - The company is focusing on expanding its pediatric product line under the "Longmu" brand, with a key product being Longmu Bone Strengthening Granules, which is a unique offering in the market[32]. - The company has launched several new prescription products, including Baidu Shengji San and Qirui Weishu Capsules, which are expected to strengthen the product foundation for future growth[34]. - The company has developed a new product, Longmu Zhuanggu Granules, aimed at treating pediatric rickets and related conditions, with a patent valid until July 22, 2034[116]. Market Strategy - The company plans to optimize its business structure, focusing on high-margin products and new product sales[21]. - The OTC product line, particularly the "Jianmin" brand, is expected to see continued growth, with products like 便通胶囊 and 健脾生血颗粒 gaining market traction[33]. - The company aims to enhance its market presence in the pediatric segment, targeting over 40 existing pediatric products in 2025[33]. Compliance and Governance - The company emphasizes compliance with securities market laws and regulations to prevent future violations[173]. - The company has established strict insider information management systems, with no insider trading incidents reported during the period[165]. - The company has implemented a cash dividend policy, distributing a total of RMB 138,058,740 to shareholders, which corresponds to a cash dividend of RMB 9 per 10 shares[187]. Challenges and Risks - The pharmaceutical industry faces challenges such as intensified price competition and increased compliance costs, which may pressure profit margins[146]. - The company faces risks from industry policy changes, intensified market competition, and raw material price fluctuations, necessitating proactive risk management strategies[154][155]. - New product introductions may not meet expectations due to market demand and consumer recognition challenges, requiring thorough market research and tailored sales strategies[155].

健民药业集团股份有限公司 关于召开 2025 年年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证券代码：600976 证券简称：健民集团 公告编号：2026-003 会议召开时间：2026 年 03 月 23 日(星期一)下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2026 年 03 月 17 日(星期二)至 03 月 20 日(星期五)16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （ir.jmjt@whjm.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 健民药业集团股份有限公司（以下简称"公司"）将于 2026 年 03 月 21 日发 布公司《2025 年年度报告》，为便于广大 ...

Core Insights - The announcement by the Hubei Provincial Drug Administration indicates that two companies, Jianmin Group Yekaitai Pharmaceutical (Suizhou) Co., Ltd. and Hubei Tianji Pharmaceutical Co., Ltd., have passed the GAP (Good Agricultural Practices) extension inspection for traditional Chinese medicine materials [3][4] Group 1: Company Information - Jianmin Group Yekaitai Pharmaceutical (Suizhou) Co., Ltd. is involved in the production of traditional Chinese medicine materials, specifically for the herb "Lianqiao" (Forsythia) with a cultivation area of 3,200 mu [3] - Hubei Tianji Pharmaceutical Co., Ltd. specializes in traditional Chinese medicine pieces, particularly "Chaihu" (Bupleurum) with a cultivation area of 3,500 mu [4] Group 2: Inspection Results - Both companies have been evaluated and found to meet the required standards for GAP, which is essential for ensuring the quality of traditional Chinese medicine production [3][4] - The inspection results include specific geographic coordinates for the cultivation bases, indicating precise locations for compliance verification [3][4]

Group 1 - The core point of the article is that Jianmin Group (600976.SH) has approved a donation of 1.5 million RMB to the China Health Promotion Foundation to support research projects related to children's respiratory and pharmaceutical studies [1] Group 2 - The donation is intended to be funded from the company's own resources [1] - The decision was made during the 11th Board of Directors' sixth meeting held on January 23, 2026 [1]

Group 1 - The core point of the article is that Jianmin Group (600976.SH) has approved a donation of 1.5 million RMB to the China Health Promotion Foundation to support research projects related to children's respiratory and pharmaceutical studies [1] Group 2 - The donation is intended to be funded from the company's own resources [1] - The decision was made during the 11th Board's 6th meeting held on January 23, 2026 [1]

Group 1 - The company, Jianmin Group, held its 11th sixth board meeting on January 23, 2026, via communication methods [1] - The meeting reviewed a proposal regarding a donation to the China Health Promotion Foundation [1] Group 2 - Local state-owned assets have begun to "bottom-fish" in the auction housing market, purchasing over 60 properties in the Nansha District of Guangzhou at prices around 6,000 to 7,000 yuan per unit [1] - The average listing price for second-hand houses in the same community exceeds 20,000 yuan [1]

证券代码：600976 证券简称：健民集团 公告编号：2026-002 捐赠金额：150 万元 中国健康促进基金会是中华人民共和国国务院批准、国家卫生健康委员会主管、 于 2006 年 12 月在国家民政部注册登记的公益慈善组织。2021 年，被民政部评为 4A 级全国性社会组织，2023 年，被国家卫生健康委直属机关党委评为先进基层党组织。 二、捐赠的基本情况 健民药业集团股份有限公司 关于对外捐赠的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司于 2026 年 1 月 23 日召开第十一次董事会第六次会 议，会议全票审议通过《关于向中国健康促进基金会捐赠的议案》，公司拟以自有资 金向中国健康促进基金会捐赠人民币 150 万元，用于支持儿童呼吸与药学相关课题 研究项目，具体如下： | 名称 | 中国健康促进基金会 | 法定代表人 | 韩萍 | | --- | --- | --- | --- | | 注册资金 | 壹仟柒佰万元整 | 社会组织类型 | 基金会 | | 设立时间 | 2006 ...

证券代码：600976 证券简称：健民集团 公告编号：2026-001 健民药业集团股份有限公司 1、关于向中国健康促进基金会捐赠的议案 同意：9 票 弃权：0 票 反对：0 票 公司拟以自有资金向中国健康促进基金会捐赠人民币 150 万元，用于支持儿童 呼吸与药学相关课题研究项目。详见中国证券报、证券时报、上海证券报及上海证 券交易所网站(http://www.sse.com.cn)《健民药业集团股份有限公司关于对外捐赠 的公告》。 二○二六年一月二十四日 特此公告。 健民药业集团股份有限公司 第十一届董事会第六次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 董事会 健民药业集团股份有限公司于 2026 年 1 月 21 日发出召开第十一届董事会第六 次会议的通知，并于 2026 年 1 月 23 日以通讯方式召开本次会议，会议应参与表决 的董事 9 人,实际参与表决的董事 9 人，符合《公司法》和《公司章程》的规定。经 到会董事充分讨论，审议通过如下议案： ...